The following is a summary of “Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies,” published in the April 2025 issue of Journal of Rheumatology by Volkmann et al.
The post Serological Profiles and Progression in Systemic Sclerosis-Associated Interstitial Lung Disease first appeared on Physician’s Weekly.
